$AMRN - On our trading list. Good longer-term healthcare growth play with volatility.Roth Capital 'confident' Amarin will obtain broad label in U.S. for VascepaRoth Capital analyst Yasmeen Rahimi said Amarin's (AMRN) continued news flow, particularly the announcement of the EMA's acceptance of Vascepa's MAA ahead of the December 28 PDUFA date, marks the strong execution of the team as they keep their eye close to the regulatory ball. Rahimi tells investors in a research note that she has confidence in Vascepa obtaining a broad label in the U.S., which sets Amarin up for a strong M&A interest from the EU, especially given the Novartis (NVS) inclisiran deal last week. She keeps a Buy rating and $31 price target on the shares. $AMRN, Amarin Corporation plc / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page